STONY BROOK, NY / ACCESS Newswire / August 14, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a biotechnology company focused on providing nucleic acid production solutions for the biopharmaceutical and diagnostics industries, today reported financial results for its third quarter of fiscal 2025 ended June 30, 2025. The Company's Form 10-Q for its fiscal third quarter can be viewed on the... Read More

STONY BROOK, NY / ACCESS Newswire / July 24, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in synthetic DNA manufacturing powered by scalable PCR platforms, today announced it received a seventh follow-on order valued at more than $600,000 for a multi-gram quantity of LineaDNA™. The follow-on order was placed by a global manufacturer of in vitro diagnostics (IVDs) under a... Read More

STONY BROOK, NY / ACCESS Newswire / July 7, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (the "Company"), a leader in PCR-based DNA technologies, today announced that on July 2, 2025, it received written notice (the "Compliance Notice") from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires that companies listed on the Nasdaq... Read More

Conducts 27% Workforce Reduction, Ceases Operations at Applied DNA Clinical Labs, Positions LineaRx for Growth STONY BROOK, NY / ACCESS Newswire / June 30, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN), a leader in PCR-based DNA technologies, announced a strategic restructuring and realignment of resources to focus exclusively on its synthetic DNA manufacturing business, LineaRx . As part of actions undertaken, the Company... Read More

President and COO Judy Murrah Appointed New Chairperson of the Board of Directors and CEO STONY BROOK, NY / ACCESS Newswire / June 17, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that Chairperson and Chief Executive Officer Dr. James A. Hayward is retiring from the Company and will step down from the Board of Directors effective... Read More

STONY BROOK, NY / ACCESS Newswire / June 16, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it will resume a regular quarterly investor call schedule, beginning with the release of its fiscal third quarter 2025 financial results in mid-August 2025. In alignment with this resumption, the Company has cancelled its previously... Read More

STONY BROOK, NY / ACCESS Newswire / May 29, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, is rescheduling its intra-quarter webcast and investor update call to June 17, 2025, from June 3, 2025, to allow for the implementation of a reverse stock split that will become effective on June 2, 2025. Prepared remarks by members of... Read More

STONY BROOK, NY / ACCESS Newswire / May 29, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding common stock. The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on June 2, 2025, and Applied DNA common stock will begin trading on a... Read More

Therapeutic DNA Production Services Segment (LineaRx) Revenues Up 44% Y/Y, Contributing to a 6% Increase in Total Revenues Intra-Quarter Investor Conference Call and Webcast Scheduled for June 3, 2025, at 4:30 PM ET STONY BROOK, NY / ACCESS Newswire / May 15, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today reported financial results for its... Read More

STONY BROOK, NY / ACCESS Newswire / May 14, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, will release its financial results for the second quarter of fiscal year 2025 (ended on March 31, 2025) after the close of the U.S. equity markets on Thursday, May 15, 2025. The Company's Form 10-Q for the period will be filed... Read More

Pivot to U.S.-based Supply Chain for Critical Input Materials Completed STONY BROOK, NY / ACCESS Newswire / April 21, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that LineaRx, Inc., the Company's majority-owned subsidiary, has completed a long-term initiative to source critical input materials for its LineaDNA™ and LineaIVT™ platforms... Read More

STONY BROOK, NY / ACCESS Newswire / April 8, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on April 7, 2025, it received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq"), informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule... Read More

Company Revamps Pharmacogenomics Go-To-Market Strategy, Targets Validated PGx Assay Towards Specific Use Cases STONY BROOK, NY / ACCESS Newswire / April 1, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that Applied DNA Clinical Labs (ADCL), its wholly-owned clinical laboratory subsidiary, is repositioning its TR8™ PGx pharmacogenomics... Read More

STONY BROOK, NY / ACCESS Newswire / March 26, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that Applied DNA Clinical Labs (ADCL), the Company's wholly-owned clinical laboratory subsidiary, has submitted a validation package to the New York State Department of Health (NYSDOH) to request approval as a laboratory-developed test (LDT) for... Read More

STONY BROOK, NY / ACCESS Newswire / March 12, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that it will effect a 1-for-50 reverse stock split of its issued and outstanding common stock. The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on Friday, March 14, 2025, and Applied DNA common stock will begin trading on... Read More

Announces Exit of DNA Tagging and Security Products and Services Business Segment Workforce Reduction of 20% of Headcount Implemented in January GMP Site 1 Facility Complete and Certified for Commercial Operation in January Webcast and Conference Call Scheduled for today at 4:30 PM ET STONY BROOK, NY / ACCESS Newswire / February 13, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in... Read More

Investor Call and Webcast Scheduled for 4:30 P.M ET STONY BROOK, NY / ACCESS Newswire / February 12, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its first quarter fiscal 2025 financial results after the market close on Thursday, February 13, 2025. The Company will host a conference call... Read More

STONY BROOK, NY / ACCESS Newswire / February 11, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today issued a reminder to its shareholders to vote ahead of a reconvening of a Special Meeting of Stockholders (the "Special Meeting") to be held on Friday, February 14, 2025 at 11:00 a.m. The Company's Board of Directors encourages any shareholder as of... Read More

Signals Start of New Commercialization Phase for LineaRx Subsidiary Company Negotiating GMP Supply Agreement Company Reaffirms Strategic Restructuring Timeline STONY BROOK, NY / ACCESSWIRE / January 10, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the completion of the buildout of its new Good Manufacturing Practices (GMP)... Read More

Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies STONY BROOK, NY / ACCESSWIRE / December 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, announced that the State Institute for Drug Control of the Czech Republic ( SÚKL ) approved an application for a Phase I clinical... Read More

Pursuing Divestiture of CertainT® Platform, Implements Changes to Corporate Leadership Build-out of GMP Manufacturing Facility to be Completed by January 9, 2025 Webcast and Conference Call Scheduled for Thursday, January 9, 2025, at 4:30 PM ET STONY BROOK, NY / ACCESSWIRE / December 17, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today reported... Read More

STONY BROOK, NY / ACCESSWIRE / December 16, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its fourth quarter and fiscal year 2024 financial results after the market close on Tuesday, December 17, 2024. The Company will host a conference call for the investment community to coincide with an... Read More

STONY BROOK, NY / ACCESSWIRE / October 30, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the pricing of a registered direct offering and concurrent private placement with gross proceeds to the Company expected to be approximately $6.5 million before deducting placement agent fees and other estimated expenses payable by the Company.... Read More

STONY BROOK, NY / ACCESSWIRE / October 15, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA"), a leader in PCR-based DNA technologies, today announced that Dr. James A. Hayward, president and chief executive officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit. Maxim Group LLC is presenting the virtual summit from October 15 th to 17 th . Jason McCarthy, Ph.D., Maxim's senior... Read More

STONY BROOK, NY / ACCESSWIRE / September 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on September 17, 2024, it received a notification letter (the "Notification Letter") from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq"), informing the Company that it has regained compliance with the minimum bid price requirement... Read More

Co-Hosts Seminar with mRNA CDMO Kudo Bio to Demonstrate Linea IVT Capability for Rapid mRNA Manufacturing STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced its participation at upcoming mRNA events in Boston this week: 3 rd Annual mRNA Process Development & Manufacturing Summit - members of Applied DNA's... Read More

Recurring and Accelerated Receipt of Order Reflects Customer Commitment to Linea DNA STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced it has received a follow-on order valued at more than $500,000 for a quantity of Linea™ DNA from a global manufacturer of in vitro diagnostics (IVDs). The... Read More

STONY BROOK, NY / ACCESSWIRE / September 11, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has launched an expansion of its clinical testing services for the detection of Mpox (formerly monkeypox) to include testing for both mpox Clade I and Clade II. The launch... Read More

Pilot Project To Demonstrate Effectiveness of CertainT® for Cotton Textile Traceability STONY BROOK, NY / ACCESSWIRE / September 4, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced the receipt of a subcontract award from LRQA following a competitive tender for a pilot isotopic testing program. Under the terms of the subcontract, Applied DNA, together with... Read More

Validation Studies Confirmed the Assay Can Detect Mpox Clade I and Clade Ib in addition to Clade II STONY BROOK, NY / ACCESSWIRE / August 23, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (the "Company"), a leader in PCR-based DNA technologies, today announced that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has submitted a validation package to the New York State Department of... Read More

STONY BROOK, NY / ACCESSWIRE / August 19, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced its intention to seek an expansion of the approved intended use of its Linea™ Mpox Virus 1.0 Assay (the "Assay") to include the detection of mpox Clade I that is the subject of the World Health Organization's (WHO) 14 August 2024 declaration of a public health... Read More

Conference Call/Webcast Scheduled for Today at 4:30 PM ET STONY BROOK, NY / ACCESSWIRE / August 8, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for its third fiscal quarter ended June 30, 2024. The Company's Form 10-Q can be viewed at https://investors.adnas.com/sec-filings/ . Third Quarter Operational... Read More

STONY BROOK, NY / ACCESSWIRE / August 7, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its third quarter fiscal 2024 financial results after market close on Thursday, August 8, 2024. In conjunction with this announcement, Applied DNA management will host a conference call for analysts and... Read More

This Version Removes the Use of 'Presentation' from the Prior-issued Headline Linea™ IVT Platform Delivers All The Benefits of Conventional IVT Without dsRNA Contamination STONY BROOK, NY / ACCESSWIRE / July 29, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, will present a poster at the 4 th Annual mRNA-based Therapeutics Summit taking place July 29 - 31, 2024, in... Read More

Linea™ IVT Platform Delivers All The Benefits of Conventional IVT Without dsRNA Contamination STONY BROOK, NY / ACCESSWIRE / July 29, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, will present a poster at the 4 th Annual mRNA-based Therapeutics Summit taking place July 29 - 31, 2024, in Boston. The poster presents the Company's Linea™ IVT platform - a combination of an... Read More

Indus Group Consumes Approximately 450 Million Pounds of Cotton Annually for the Manufacture of Apparel, Footwear, and Accessories for Global Brands and Retailers STONY BROOK, NY / ACCESSWIRE / July 25, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the signing of a five-year license and commercialization agreement for its CertainT ®... Read More

STONY BROOK, NY / ACCESSWIRE / July 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that the U.S. Defense Logistics Agency (DLA) exercised the first one-year option period of a three-year base contract with two one-year option periods entered into in May 2021. The contract supports DLA's counterfeit mitigation initiatives and product verification and... Read More

Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability Applied DNA Secures Commercial Linea RNAP Quantity Sufficient to Support Anticipated Near-Term Demand STONY BROOK, NY AND JUPITER, FL / ACCESSWIRE / June 20, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, and Alphazyme LLC... Read More

Partnership Will Aid Physicians in Precision Prescribing Decisions Based on Applied DNA's TR8™ Pharmacogenomic (PGx) Test STONY BROOK, NY / ACCESSWIRE / June 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a global leader in PCR-based DNA technologies, today announced that its molecular diagnostics subsidiary, Applied DNA Clinical Labs, LLC (ADCL), will utilize the GenXys Health Care Systems (GenXys) suite... Read More

STONY BROOK, NY / ACCESSWIRE / June 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that the New York State Department of Health ("NYSDOH") approved the Company's TR8™ PGx ("TR8") pharmacogenomic (PGx) testing service. The Company is currently in discussions to provide large-scale testing to enterprise customers, healthcare... Read More

Patent covers the Composition of the Company's Proprietary Linea™ RNAP, a Core Technology Empowering the Linea™ IVT Platform Patent Application Also Currently Pending in Key International Markets STONY BROOK, NY / ACCESSWIRE / June 5, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, announced today that it received a Notice of Allowance from the United... Read More

STONY BROOK, NY / ACCESSWIRE / May 28, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the pricing of a public offering with gross proceeds to the Company expected to be approximately $12.0 million, before deducting placement agent fees and other estimated expenses payable by the Company. The offering is comprised of 9,230,769 Units... Read More

STONY BROOK, NY / ACCESSWIRE / May 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, and the Institute of Hematology and Blood Transfusion ( ÚHKT/IHBT ) today announced that an abstract relating to the development of a fully enzymatic, non-viral manufacturing workflow to enable the rapid and cost-effective production of clinical-grade (GMP) CAR T-cell therapies has... Read More

STONY BROOK, NY / ACCESSWIRE / May 10, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for its second fiscal quarter ended March 31, 2024. The Company's Form 10-Q can be viewed at https://investors.adnas.com/sec-filings/ . The Company will not host a financial webcast or call for this most recent quarterly... Read More

STONY BROOK, NY / ACCESSWIRE / May 10, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on May 9, 2024, it received a notification letter (the "Notification Letter") from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq"), informing the Company that it has regained compliance with the minimum bid price requirement set forth in... Read More

Award Seeks to Demonstrate Feasibility of Manufacturing mRNA Vaccines in Only 7 Days STONY BROOK, NY / ACCESSWIRE / April 25, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced the award of a contract from HDT Bio for the purpose of rapid, next-generation vaccine development under a ‘Project NextGen: Enabler' award to HDT Bio (the "Project"). The Project... Read More

STONY BROOK, NY / ACCESSWIRE / April 22, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the Company), a leader in PCR-based DNA technologies, today announced that it will effect a 1-for-20 stock split of its common stock, to be effective as of 12:01 a.m. Eastern Time on Thursday, April 25, 2024. Applied DNA common stock will begin trading on a split-adjusted basis commencing upon market open on Thursday,... Read More

Project To Increase RNAP Manufacturing Capacity and Reduce Unit Costs of Goods Project Slated for Completion Coincident with Company's Planned Initiation of GMP Manufacturing for Linea™ DNA IVT Templates STONY BROOK, NY and JUPITER, FL / ACCESSWIRE / March 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the Company), a leader in PCR-based DNA technologies, and Alphazyme LLC (Alphazyme), a Maravai... Read More

STONY BROOK, NY / ACCESSWIRE / March 14, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, will showcase its Linea™ IVT and Linea™ DNA platforms at the 24 th Annual World Vaccine Congress, which will be held April 1 - 4, 2024. Applied DNA sales team members will be available during the Congress for one-on-one meetings. Location: Walter E. Washington Convention Center,... Read More

Company On Track to Initiate First-Phase GMP Production Capacity for mRNA Critical Starting Materials During First Half of Calendar 2024, Projects Initial Facility Capacity to Enable up to $15 Million 1 of Linea IVT Revenue 2 Annually Conference Call/Webcast Scheduled for Today at 4:30 PM ET STONY BROOK, NY / ACCESSWIRE / February 8, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader... Read More

STONY BROOK, NY / ACCESSWIRE / February 5, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its first quarter fiscal 2024 financial results after market close on Thursday, February 8, 2024. In conjunction with this announcement, Applied DNA management will host a conference call for analysts... Read More

STONY BROOK, NY / ACCESSWIRE / February 2, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that it has closed its previously announced registered direct offering of its common stock priced at-the-market under Nasdaq rules with certain existing institutional investors (collectively the "Holders") for the sale of an aggregate of 5,644,061 of its shares of... Read More

STONY BROOK, NY / ACCESSWIRE / January 31, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that it has entered into securities purchase agreements (SPAs) with certain existing institutional investors (collectively the "Holders") for the issuance and sale of an aggregate of 5,644,061 of its shares of common stock (or prefunded warrants in lieu thereof) at... Read More

Agreement Seeks to Leverage Linea IVT Platform to Enable Kudo Bio to Offer a Differentiated mRNA Manufacturing Capability with Mitigated dsRNA and Reduced Turnaround Times STONY BROOK, NY and NEEDHAM, MA / ACCESSWIRE / December 14, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, and Kudo Biotechnology (Kudo Bio), a leading global mRNA CDMO offering end-to-end cGMP mRNA... Read More

Conference Call/Webcast Scheduled for Today at 4:30 PM ET STONY BROOK, NY / ACCESSWIRE / December 7, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for its fourth quarter ended September 30, 2023. "Our fiscal fourth quarter concludes a productive year during which we took a number of critical steps that... Read More

STONY BROOK, NY / ACCESSWIRE / December 5, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its fourth quarter and full year financial results 2023 ended September 30, 2023, on Thursday, December 7, 2023, after the market close. The Company will host a conference call for the investment... Read More

STONY BROOK, NY / ACCESSWIRE / November 28, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the receipt of a follow-on order for Linea™ DNA valued above the mid-six figures. The order was placed under a long-standing supply agreement for the bulk manufacture of Linea DNA (non-therapeutic) for a global manufacturer of in vitro... Read More

Extension Increases Total Addressable Market to Include Both Conventional Non-Amplifying mRNA and saRNA Extension Enabled by the Company's Ongoing Platform Development and Optimization STONY BROOK, NY / ACCESSWIRE / November 16, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, announced the expansion of its Linea™ IVT platform (the "Platform") to... Read More

Preclinical Orders for Additional Customers Underway STONY BROOK, NY / ACCESSWIRE / November 9, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it has successfully manufactured and shipped its first research use only quantity of self-amplifying mRNA (saRNA) template generated by its Linea™ DNA platform (the "Platform") to an... Read More

Agreement Focuses on the Accelerated Development of LNP-encapsulated LineaDNA™ Vaccines to Eliminate the Use of Plasmid DNA and Reduce the Dependence on Extreme Cold Chains of Today's mRNA Vaccines STONY BROOK, NY and ITHACA, NY / ACCESSWIRE / September 14, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (‘Applied DNA' or the "Company"), a leader in polymerase chain reaction ("PCR")-based technologies, and the Cornell... Read More

Experienced Biopharma/Pharmaceutical Executive to Lead Implementation of cGMP-quality LineaDNA™ Capability for IVT mRNA Production Previously Led Manufacturing Operations Scale-up for the BioNTech/Pfizer mRNA COVID-19 Vaccine at CDMO Division of Maravai LifeSciences STONY BROOK, NY / ACCESSWIRE / September 6, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA... Read More

STONY BROOK, NY / ACCESSWIRE / August 29, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the general availability of Linea™ IVT platform evaluation kits (the "Kit") and the first shipment of a Kit to an existing Linea™ IVT Template customer. The newly launched Kit, comprised of Linea™ IVT template, a buffer system, and Linea™ RNA... Read More

STONY BROOK, NY / ACCESSWIRE / August 23, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the filing with the United States Patent and Trademark Office of two provisional patent applications claiming compositions of matter and methods to reduce or potentially eliminate double-stranded RNA (dsRNA) byproducts generated during the... Read More

Conference Call/Webcast Scheduled for Today at 4:30 PM ET STONY BROOK, NY / ACCESSWIRE / August 10, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for the third quarter of fiscal 2023 ended June 30, 2023. "Our fiscal third quarter performance stands out for the substantial progress made to advance the... Read More

STONY BROOK, NY / ACCESSWIRE / August 7, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release financial results for the three months ended June 30, 2023 after the market close on Thursday, August 10, 2023. The Company will host a conference call for the investment community to discuss the results... Read More

STONY BROOK, NY / ACCESSWIRE / July 18, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA"), a leader in PCR-based DNA technologies, today announced the participation of LineaRx, Inc., its majority-owned biotherapeutics subsidiary, in upcoming mRNA industry conferences in Boston: July 26 - 28, the mRNA-Based Therapeutics Summit at the Boston Convention and Exhibition Center and The Westin Boston Seaport.... Read More

Platform Enables Customers to Manufacture mRNA with Substantial Reduction in dsRNA and Manufacturing Complexities; Integrable into Current mRNA Workflows Platform Currently Available Under Early Access Program STONY BROOK, NY / ACCESSWIRE / July 13, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it has acquired Spindle Biotech... Read More

STONY BROOK, NY / ACCESSWIRE / June 8, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA"), a leader in PCR-based DNA technologies, today announced that it has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on June 20-22, 2023. Dr. James A. Hayward, president and CEO, of Applied DNA, will participate in a Fireside Chat hosted by Maxim Group... Read More

linearDNA™ Gaining Momentum as a Differentiated DNA Template for mRNA Production, Company Identifies Early Development-Stage Acquisition Target to Potentially Expand Commercial Advantages Balance of CY23 Set Up for Multiple Value Inflection Points Conference Call/Webcast Scheduled for Today at 4:30 PM ET STONY BROOK, NY / ACCESSWIRE / May 11, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a... Read More

STONY BROOK, N.Y. / May 03, 2023 / Business Wire / Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release financial results for the three months ended March 31, 2023 after the market close on Thursday, May 11, 2023. The Company will host a conference call for the investment community to discuss the... Read More

STONY BROOK, N.Y. / Apr 07, 2023 / Business Wire / Applied DNA Sciences, Inc. (NASDAQ: APDN) (the "Company"), a leader in PCR-based DNA technologies, announced that its CertainT® supply chain traceability platform is featured in an article on the home page of the New York Times website today. The article, titled "How A.I. and DNA Are Unlocking the Mysteries of Global Supply Chains," centers on the mounting need for the... Read More

STONY BROOK, N.Y. / Mar 29, 2023 / Business Wire / Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced that it has established a new high bar for the production of DNA with the manufacture and shipment of a multi-gram quantity of linearDNA™ in under six weeks. The quantity was produced by the Company’s LinearDNA™ platform under a large recurring purchase order... Read More

Expansion of Population-Scale Molecular Diagnostics Menu Positions ADCL Subsidiary for Long-Term Growth STONY BROOK, N.Y. / Mar 22, 2023 / Business Wire / Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has submitted a validation package to the New York State... Read More

STONY BROOK, N.Y. / Feb 10, 2023 / Business Wire / Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced the receipt of an up to $1.5 million award from New York State’s Empire State Development (ESD) agency. The award is provided by ESD under the Excelsior Jobs Program for qualifying net new job creation as refundable employee tax credits claimed over a benefit... Read More

STONY BROOK, N.Y. / Feb 09, 2023 / Business Wire / Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced consolidated financial results for the first quarter of fiscal 2023, ended December 31, 2022. “Applied DNA delivered a solid start to the fiscal year with sequential and year-over-year revenue growth driven by molecular diagnostic testing demand... Read More

STONY BROOK, N.Y. / Feb 02, 2023 / Business Wire / Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction ("PCR")-based technologies, today announced that it will release financial results for the three months ended December 31, 2022, after the market closes on Thursday, February 9, 2023. The Company will host a conference call for the investment community to discuss... Read More

Company Advances Lipid Nanoparticle (LNP)-based Delivery System to Potentially Broaden LinearDNA Platform Commercial Utility Applied DNA Sciences, Inc. ( NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced the publication of a peer-reviewed research article in Molecular Therapy – Methods & Clinical Development . The study, titled ‘A linear DNA vaccine candidate encoding the SARS-CoV-2... Read More

Delivers 17% Revenue Growth Q/Q and 101% Y/Y Cash and Cash Equivalents at $15.2 Million Company to Hold Conference Call and Webcast Today, Wednesday, December 14, 2022, at 4:30 PM ET STONY BROOK, N.Y.--( BUSINESS WIRE )-- Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced consolidated financial results for the fourth quarter and fiscal year... Read More